Skip to main content
Premium Trial:

Request an Annual Quote

TimeLogic Inks Hardware Agreement with Bielefeld University for Computational Biology Research

Premium

Active Motif's TimeLogic said this week that Bielefeld University's Center for Biotechnology has purchased one of its DeCypher systems to support research aimed at discovering new functions of genes and proteins.

TimeLogic’s DeCypher systems use a combination of field programmable gate array-based PCIe accelerator cards and servers to run implementations of Blast, Smith-Waterman, hidden Markov model, and gene modeling algorithms.

Alexander Goesmann, executive director of the bioinformatics resource facility at CeBiTec, said that the institute is "confident that the new systems will boost our compute capacities to facilitate the analysis of microbial and eukaryotic genomes as well as metagenomes” as well as to mine biological data repositories.

Goesmanm said that the DeCypher system has already reduced "the time needed for a full-blown annotation of a bacterial genome" from several hours to less than an hour.

He expects that there will be "further improvements" to the system once the center's "internal compute job processing and scheduling" are optimized.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.